Showing posts with label Estimation of State-Level Prevalence of Hepatitis C Virus Infection. Show all posts
Showing posts with label Estimation of State-Level Prevalence of Hepatitis C Virus Infection. Show all posts

Thursday, January 17, 2019

Level Maps Showing Impact of Hepatitis C Epidemic Across the U.S.

HepVu Releases State-Level Maps Showing Impact of Hepatitis C Epidemic Across the U.S.

ATLANTA, Jan. 16, 2019 – Today, HepVu launched new interactive maps visualizing state-level estimates of people living with Hepatitis C across the United States that highlight a concentration of infections in some states most impacted by the opioid epidemic. Published in JAMA Network Open, the data reveal an estimated 2.3 million people living with Hepatitis C infection in the U.S. between 2013 and 2016, with a high burden in the West and in some Appalachian states.

“We still have more than 2 million people living with Hepatitis C at a time when ending this epidemic is possible,” said Patrick Sullivan, Ph.D., DVM, Professor of Epidemiology at Emory University’s Rollins School of Public Health and Principal Scientist for AIDSVu. “Hundreds of thousands of Americans have been cured of Hepatitis C with newly available treatments, yet new Hepatitis C infections have nearly tripled in recent years as a consequence of increasing injection drug use associated with the opioid epidemic. At the same time, many older Americans, who have been living with Hepatitis C for decades, still remain undiagnosed and untreated. Halting the Hepatitis C epidemic requires a commitment across the nation to diagnose and cure people living with the virus and stop new infections before they erode our significant progress.”

Three-fourths of Americans living with Hepatitis C are Baby Boomers (those born between 1945 and 1965). However, the largest increases in Hepatitis C infections over the last decade have been among individuals less than 40 years old and particularly among persons who inject drugs.

“Hepatitis C and other infectious diseases are often-overlooked consequences of America’s opioid crisis,” said Eli Rosenberg, Ph.D., Associate Professor of Epidemiology and Biostatistics, University at Albany School of Public Health, State University of New York. “Our analysis helps to pinpoint the concentration of the disease geographically and shows the burden of Hepatitis C is greater in places highly affected by the opioid epidemic.”

Key findings include:
-The Western U.S. has the highest rate of people with evidence of Hepatitis C infection, with 10 of the region’s 13 states having an estimated Hepatitis C prevalence above the national median.
-There is also a concentration of Hepatitis C in Appalachia, likely related to the opioid epidemic in these states. Kentucky, West Virginia, and Tennessee are now among the 10 hardest-hit states.
-Nine states (California, Florida, Michigan, New York, North Carolina, Ohio, Pennsylvania, Tennessee, and Texas) represent more than half, or 52 percent of all persons with Hepatitis C nationally – and five of the nine states are in Appalachia.

“One of the most critical challenges in our national response to viral hepatitis is limited data that we can use to understand and monitor the epidemic,” continued Sullivan. “Accurate estimates of the burden of Hepatitis C infection in each state are essential to inform policy, programmatic, and resource planning for elimination strategies across the U.S. By mapping Hepatitis C in the U.S., HepVu seeks to provide a comprehensive picture of the disease’s impact on states to inform researchers and public health decision-makers’ prevention and care efforts.”

HepVu is a Powered By AIDSVu project presented by Emory University’s Rollins School of Public Health in partnership with Gilead Sciences, Inc. State-level Hepatitis C prevalence estimates on HepVu can be viewed alongside social determinants of health and data related to the opioid epidemic, including opioid prescription rate, narcotic overdose mortality rate, and pain reliever misuse prevalence. HepVu also visualizes data on Hepatitis C-related mortality (2016) obtained from the Centers for Disease Control and Prevention’s (CDC) WONDER Online Database System. Additionally, HepVu offers downloadable datasets for researchers and health departments to utilize in their own analyses, infographics on Hepatitis B and C, and state-specific factsheets.

The state-level Hepatitis C prevalence estimates displayed on HepVu are produced by the Emory University Coalition for Applied Modeling for Prevention (CAMP) project with researchers from the University of Albany and developed with CDC. Findings were published in the peer-reviewed Journal of the American Medical Association (JAMA) Network Open in an article titled, “Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2013 – 2016”.

The new data are derived using an updated approach to the previously published methodology for 2010 state-specific Hepatitis C prevalence estimation that reflects current changes to the epidemic. To estimate state-level Hepatitis C prevalence, researchers analyzed blood test results from the nationally representative National Health and Nutrition Examination Survey (NHANES) and vital statistics data from 2013 through 2016, and incorporated data on Hepatitis C-related deaths and narcotic overdose deaths. The researchers also estimated the number of Hepatitis C infections among populations not included in NHANES, including incarcerated, unsheltered homeless, and nursing home resident populations. For more information on the data methods, please visit

Wednesday, April 26, 2017

Q&A: First U.S. state-by-state analysis of hepatitis C cases

Media Coverage
Q&A: First U.S. state-by-state analysis of hepatitis C cases
By Jon Cohen
Apr. 26, 2017 , 12:00 PM
In the infectious disease world, the liver-damaging hepatitis C virus (HCV) long has lived in the shadows of killers such as HIV/AIDS, tuberculosis, and malaria. But curative—and expensive—HCV drugs that have come to market over the past 5 years have focused new attention on the deadly disease.

Now, for the first time, researchers have mapped its U.S. prevalence state-by-state. They hope their model ultimately will help improve targeting of efforts to screen for the virus and treat the more than 3 million people in the country who are living with the infection.
Estimation of State-Level Prevalence of Hepatitis C Virus Infection, US States and District of Columbia, 2010
Eli S. Rosenberg Eric W. Hall Patrick S. Sullivan Travis H. Sanchez Kimberly A. Workowski John W. Ward Deborah HoltzmanClin Infect Dis cix202.

Published: 26 April 2017

Full Text

Hepatitis C virus (HCV) infection is the most common chronic blood-borne infection in the United States and a leading cause of morbidity and mortality. Previous analyses of the US National Health and Nutrition Examination Survey (NHANES) indicated approximately 3.6 million noninstitutionalized persons with antibody to HCV (anti-HCV). However, state-level prevalence remains less understood and cannot be estimated reliably from NHANES alone.
We used 3 publicly available government data sources to estimate anti-HCV prevalence in each US state among noninstitutionalized persons aged ≥18 years. A small-area estimation model combined indirect standardization of NHANES-based prevalence with logistic regression modeling of mortality data, listing acute or chronic HCV infection as a cause of death, from the National Vital Statistics System during 1999–2012. Model results were combined with US Census population sizes to estimate total number and prevalence of persons with antibody to HCV in 2010.
National anti-HCV prevalence was 1.67% (95% confidence interval [CI], 1.53–1.90), or 3 911 800 (95% CI, 3 589 400– 4 447 500) adults in 2010. State-specific prevalence ranged from 0.71% (Illinois) to 3.34% (Oklahoma). The West census region had the highest region-specific prevalence (2.14% [95% CI, 1.96–2.48]); 10 of 13 states had rates above the national average. The South had the highest number of persons with anti-HCV (n = 1561600 [95% CI, 1 427 700–1 768 900]). The Midwest had the lowest region-specific prevalence (1.14% [95% CI, 1.04%–1.30%]).
States in the US West and South have been most impacted by hepatitis C. Estimates of HCV infection burden are essential to guide policy and programs to optimally prevent, detect, and cure infection.
Continue to full text article